Bevacizumab (Avastin) for non-small cell lung cancer (nsclc) - horizon scanning review
NHSC
Record Status
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.
Citation
NHSC. Bevacizumab (Avastin) for non-small cell lung cancer (nsclc) - horizon scanning review. Birmingham: National Horizon Scanning Centre (NHSC). 2005
Authors' objectives
This study aims to summarise the currently available evidence on Bevacizumab (Avastin) for non-small cell lung cancer (nsclc).
Authors' conclusions
Bevacizumab (Avastin) is a humanised vascular endothelial growth factor (VEGF) antibody that is currently in phase III clinical trials for the first-line treatment of advanced nonsquamous, non-small cell lung cancer (nsclc) in combination with existing chemotherapy agents (carboplatin and paclitaxel). One phase II/III trial in 842 patients has reported interim results based upon 469 of the 650 planned deaths. The addition of bevacizumab resulted in a significantly increased response rate (27% versus 10%), increased progression-free survival to 6.4 months from 4.5 months, and also significantly increased median survival to 12.5 months from 10.2 months.
Bevacizumab is launched in the EU as first-line therapy for metastatic colorectal cancer in combination with conventional cytotoxic chemotherapy. It is also in phase III clinical trials for first-line treatment of breast cancer with paclitaxel and as second-line therapy in metastatic renal cell cancer with or without interferon alfa.
Department of Public Health&Epidemiology, The University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom. Tel: +44 121 414 7831; Fax: +44 121 414 2269; Email: c.packer@bham.ac.uk